When the lining of the uterus does not reach the expected thickness, planning an embryo transfer can become difficult. Intrauterine G-CSF is one option that may be discussed in selected cases after a physician’s assessment. Here is what studies have found so far and what guidelines say.
Why does endometrial thickness matter?
The endometrium is the lining of the uterus, where an embryo implants, and it is monitored by ultrasound during IVF. A cut-off of 7 mm is commonly used to define a thin endometrium, although there is no full consensus on it. Measurements below 7 mm have been associated with a lower chance of pregnancy, but no specific thickness has been shown to rule out pregnancy on its own.
Causes vary: age and hormonal influences, an inflammatory environment inside the uterus, long-term use of oral contraceptives or ovulation-inducing drugs and, in some women, no known reason. The first step is therefore not choosing a treatment but understanding the cause.
What is G-CSF?
G-CSF (granulocyte colony-stimulating factor) is a growth factor that stimulates the bone marrow to produce certain white blood cells. Its use for the endometrium has been described in reproductive medicine as off-label.
Its exact effect on the endometrium is not known. It is thought to influence genes involved in blood vessel remodelling, local immune regulation and cell adhesion. Animal research has shown increased thickness, but animal data do not establish the same result in women.
What do the studies show?
- Early observation. In one of the first studies, thickness rose from 6.4 mm to 9.3 mm in 21 women who had not responded to standard treatment. The study had no comparison group.
- Increase in thickness. A 2017 meta-analysis of 11 studies and 683 patients reported a mean increase of 1.79 mm and a higher clinical pregnancy rate (risk ratio 2.52).
- More recent data. A 2025 network meta-analysis of 20 studies in women undergoing assisted reproduction found a thickness difference of 1.27 mm and an odds ratio of 2.03 for clinical pregnancy. Results were similar in the thin endometrium subgroup.
Are the results the same for every patient?
Results do not all point the same way. In 35 women with resistant thin endometrium, thickness rose from 5.86 mm to 6.58 mm and 19 proceeded to transfer, but no clinical pregnancy occurred. In a randomised study of 120 women having intrauterine insemination, 45% versus 31.67% reached 7 mm; the improvement in the G-CSF group did not reach statistical significance.
Normal thickness and unselected patients. Randomised trials found no difference in pregnancy outcomes in unselected IVF patients (141 women), in women with normal thickness (100 women) and in recurrent implantation failure with a normal endometrium (157 women). A network meta-analysis of 19 trials and 2,434 women with recurrent implantation failure also found no significant benefit. This is why it is considered for a specific problem rather than for everyone.
Live birth. Live birth is the outcome that matters most, and study results differ. A 2024 network meta-analysis reported more live births in thin endometrium (risk ratio 1.53). By contrast, an umbrella review of 47 systematic reviews on recurrent implantation failure found that G-CSF improved live birth in only 1 of 7 meta-analyses, and rated 88% of the reviews as low or critically low quality.
Dose and timing. In published studies the drug was delivered into the uterine cavity through a thin catheter. Dose and timing varied between studies; there is no single standard protocol.
Safety. Some studies reported no adverse events. However, reviews note that safety and birth outcomes have been inadequately reported and that no studies have examined long-term effects on the children’s health.
What do guidelines say?
The European Society of Human Reproduction and Embryology (ESHRE) does not recommend intrauterine G-CSF in its two 2023 documents. It points to the number of patients in the studies and differences in transfer types, and notes that data in thin endometrium differ from one another. A protocol has been published for a four-centre, sham-controlled trial of 440 women with live birth as its main outcome; results are not yet available.
G-CSF is therefore not a routine add-on. It is a case-by-case decision made by the physician in selected patients, particularly those with an endometrial thickness problem.
What this means if your lining is thin
As with every treatment, planning begins with a medical pre-assessment and/or examination and a review of test results, followed by a careful conversation with the patient. Causes such as adhesions, polyps and hormonal problems are investigated first.
No treatment can guarantee pregnancy, and a thicker lining does not by itself mean a pregnancy will follow. Review the options suited to you together with your physician. You can read more about endometrial PRP.
Sources: ESHRE good practice recommendations on add-ons, Hum Reprod 2023 (doi) · ESHRE good practice recommendations on recurrent implantation failure, Hum Reprod Open 2023 (doi) · Mouhayar and Sharara, J Assist Reprod Genet 2017 (doi) · Wang et al., Front Endocrinol 2024 (doi) · Gleicher et al., Hum Reprod 2013 (doi) · Xie et al., Am J Reprod Immunol 2017 (doi) · Xie et al., Life Sci 2020 (doi) · Li X et al., BMC Pregnancy Childbirth 2025 (doi) · Mishra et al., J Obstet Gynaecol India 2015 (doi) · Narayana et al., Med J Armed Forces India 2024 (doi) · Barad et al., Fertil Steril 2014 (doi) · Eftekhar et al., Int J Reprod Biomed 2016 (pmc) · Kalem et al., Sci Rep 2020 (doi) · Li et al., J Reprod Immunol 2026 (doi) · Li L et al., Gynecol Endocrinol 2024 (doi) · Almohammadi et al., Int J Gynaecol Obstet 2025 (doi) · Hua et al., BMJ Open 2026 (doi) · Belarmino et al., JBRA Assist Reprod 2026 (doi). This article is general information and does not replace a medical examination. Prepared with AI assistance under the medical supervision of Assist. Prof. Dr. Muzaffer Uçarer (Obstetrics and Gynaecology · IVF and Reproductive Medicine), UCARER Women’s Health, Istanbul.
